GLP2 T

GLP2 T is a synthetic dual GIP/GLP-1 receptor agonist peptide analog: one fatty acid-modified peptide that activates both incretin receptors, the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Preclinical work on this dual agonist class has examined incretin receptor signaling in cell lines, glucose-dependent insulin secretion and food intake in mice, and the ways GIP and GLP-1 receptor biology differ across islets, fat tissue and the hypothalamus. Research Market supplies the GLP2 T peptide in 5 mg, 10 mg and 15 mg vials, with purity and identity data for each lot reported on its certificate of analysis. It is sold strictly for laboratory research use.

Chemical structure and identification

• Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular weight: 4813 g/mol
• CAS number: 2023788-19-2
• PubChem CID: 166567236
• Form: Lyophilized powder
• Analytical methods: RP-HPLC for purity and mass spectrometry for identity, reported on the batch certificate of analysis

Research applications

• Dual receptor pharmacology: In its discovery report, the fatty acid-modified dual agonist LY3298176 activated both GIP and GLP-1 receptor signaling in cell assays, and in mice it produced glucose-dependent insulin secretion and improved glucose tolerance by acting on both receptors [1]
• Comparing the two incretins: GIP and GLP-1 both raise cAMP in pancreatic β-cells through their G protein-coupled receptors, while differing elsewhere: GIP enhances the postprandial glucagon response and GLP-1 suppresses it, and GIP but not GLP-1 promotes fat deposition in adipose tissue [2]
• Hypothalamic GIP receptors: In Gipr-Cre knock-in mice, Gipr-expressing cells were located in the arcuate, dorsomedial and paraventricular hypothalamic nuclei, and chemogenetic activation of these cells suppressed food intake [3]
• Incretin receptor mechanisms: Reviewed preclinical mechanisms that couple GLP-1 and GIP receptor signaling to islet hormone secretion, lipid metabolism, gut motility, appetite and immune function [4]
• GIP receptor biology: Reviewed GIP’s metabolic effects outside the endocrine pancreas and the finding that both GIP receptor agonism and antagonism have been studied in obesity and diabetes pharmacology [5]

Reference citations

1. Coskun T. et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab, 18:3–14. PMID 30473097 · DOI
2. Seino Y. et al. (2010). GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig, 1(1-2):8–23. PMID 24843404 · DOI
3. Adriaenssens A.E. et al. (2019). Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab, 30(5):987–996.e6. PMID 31447324 · DOI
4. Campbell J.E. et al. (2013). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab, 17(6):819–837. PMID 23684623 · DOI
5. Müller T.D. et al. (2025). Glucose-dependent insulinotropic polypeptide (GIP). Mol Metab, 95:102118. PMID 40024571 · DOI

Compound data from PubChem CID 166567236. Literature summaries describe published preclinical research and are not claims about this product’s effects in humans or animals.